ix) In ovarian cancer, one study found that Nrf2 can mediate the response of cancer cells to the anti-HER2 drugs, trastuzumab and pertuzumab, in ovarian cancer cells (Khalil et al., 2016). This evidence concerns the gene ERBB2 and ovarian cancer.